Tobias Joseph D
Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States.
Department of Anesthesiology and Pain Medicine, The Ohio State University College of Medicine, Columbus, Ohio, United States.
J Pediatr Intensive Care. 2020 Sep;9(3):162-171. doi: 10.1055/s-0040-1705133. Epub 2020 Mar 6.
Sugammadex is a novel pharmacologic agent, which reverses neuromuscular blockade with a mechanism that differs from acetylcholinesterase inhibitors such as neostigmine. There is a growing body of literature demonstrating its efficacy in pediatric patients of all ages. Prospective trials have demonstrated a more rapid and more complete reversal of rocuronium-induced neuromuscular blockade than the acetylcholinesterase inhibitor, neostigmine. Unlike the acetylcholinesterase inhibitors, sugammadex effectively reverses intense or complete neuromuscular blockade. It may also be effective in situations where reversal of neuromuscular blockade is problematic including patients with neuromyopathic conditions or when acetylcholinesterase inhibitors are contraindicated. This article reviews the physiology of neuromuscular transmission as well as the published literature, regarding the use of sugammadex in pediatric population including the pediatric intensive care unit population. Clinical applications are reviewed, adverse effects are discussed, and dosing algorithms are presented.
舒更葡糖钠是一种新型药物,其逆转神经肌肉阻滞的机制不同于新斯的明等乙酰胆碱酯酶抑制剂。越来越多的文献表明其在各年龄段儿科患者中均有效。前瞻性试验已证明,与乙酰胆碱酯酶抑制剂新斯的明相比,舒更葡糖钠能更快速、更完全地逆转罗库溴铵诱导的神经肌肉阻滞。与乙酰胆碱酯酶抑制剂不同,舒更葡糖钠能有效逆转深度或完全性神经肌肉阻滞。在神经肌肉阻滞逆转存在问题的情况下,包括患有神经肌肉疾病的患者或乙酰胆碱酯酶抑制剂禁忌时,它可能也有效。本文回顾了神经肌肉传递的生理学以及已发表的关于舒更葡糖钠在儿科人群(包括儿科重症监护病房人群)中应用的文献。对临床应用进行了回顾,讨论了不良反应,并给出了给药算法。